Cardiol Therapeutics Announces Study Results Confirm the Cardioprotective Role of its Pharmaceutical Cannabidiol Formulation in a Model of Heart Failure
Cardiol Therapeutics Inc. (TSX:CRDL, OTCQX:CRTPF) (“Cardiol” or the “Company”), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce that data submitted by its international research collaborators were accepted for presentation at the American College of Cardiology’s (ACC) 69th Annual Scientific Session & Expo together with the World Congress of Cardiology, held virtually from March 28-30. All accepted abstracts will be subsequently published.
The effects of Cardiol’s pharmaceutically produced (cGMP) cannabidiol formulation were assessed in a model of non-ischemic heart failure. Heart failure was induced by four weeks of infusion of angiotensin II, a substance that produces hypertension, cardiac enlargement, and subsequent heart failure. Two dosages of Cardiol’s cannabidiol formulation (or placebo) were administered by subcutaneous injection every three days for four weeks. In addition, the effects of CBD on angiotensin-induced hypertrophy (cell enlargement) and expression of B-type Natriuretic Peptide (BNP) in a cardiac cell line (H9c2) were assessed. BNP is a substance released from stretched heart cells which is a widely used clinical indicator of the severity of heart failure.
Primo Nutraceuticals Signs LOI to enter in to Funding and Share Purchase Agreement for 25 Percent with Beauty Kitchen
Primo Nutraceuticals Inc. (CSE:PRMO, OTC:BUGVF, FSE:8BV, DEU:8BV, MUN:8BV, STU:8BV) (“Primo” or the “Company”) is pleased to announce that it has signed a letter of intent (“LOI”) with Heather Marianna, LLC parent company of (“Beauty Kitchen”) a Nevada company. The Board of Directors of Primo have approved, in principle, a proposal to acquire and raise funding in respect of its interests in the “Beauty Kitchen” projects into a newly incorporated subsidiary.
Beauty Kitchen proposes a transaction whereby its management team (and affiliates) incorporates a Canadian corporation, tentatively called “Marianna, Inc.” to receive exclusive Canadian distribution rights to its CBD infused and non-CBD infused products in handmade beauty care, personal care, and cosmetic products. Primo will acquire ownership interest of a minimum of 25% in the newly incorporated subsidiary.
Heritage Cannabis Holdings Corp. (CSE:CANN) (“Heritage” or the “Company”), today announced its financial results for the three month period ended January 31, 2020 ( “Q1 2020”). All figures are in Canadian dollars unless otherwise noted.
“The first quarter showed continued growth in revenue and the advancement of our business strategy with the expansion of our licensed area at CannaCure progressing well. We completed the installation and commissioning of downstream processing equipment and are in the process of commissioning two previously purchased extraction machines,” stated Clint Sharples, Chief Executive Officer of Heritage. “We are continuing to monitor the threat that COVID-19 poses to our operations at our production facilities. We have a strong balance sheet that we believe will support the Company through this time and we have taken steps to preserve cash balances.”
Valens GroWorks Corp. (TSXV:VLNS, OTCQX:VLNCF) (the “Company”, “Valens” or “The Valens Company”), a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, is pleased to announce it has received conditional approval from the Toronto Stock Exchange (“TSX”) to uplist from the TSX Venture Exchange (“TSXV”) to the TSX.
“Graduating to the TSX represents a significant milestone in our efforts to broaden our appeal to a larger shareholder base and raise the company’s profile among the investment community,” said Tyler Robson, CEO of The Valens Company. “Coming off a record year of growth for the company, this uplisting will work to enhance the liquidity of our stock and enable us to continue building long-term shareholder value.”
Having begun sales in late 2019, Weekend branded products are now in over 75 dispensaries in the state and expanding presence daily. Oklahoma was identified as an up and coming market, a focus for the Company’s strategic plan – to develop products to meet the demands within individual markets, establish a foothold and operate in an agile manner with the best partners, creating the right branded product mix for each market. Ultimately, the Company is designed to leverage the core branded products to expand into up and coming states and to replicate the responsive model. In Oklahoma Weekend has added two highly experienced cannabis sales representatives to its team to manage and grow the Company’s expanding retail relationship network.
Ignite Expands Its CBD Product Lineup and introduces CBD Skincare Product Line in United Kingdom Trade Channels
Ignite International Brands, Ltd. (CSE:BILZ, OTCQX:BILZF) (“IGNITE” or the “Company”), a global consumer packaged goods brand, is pleased to announce that it is expanding its partnership with UK manufacturer and distributor Taylor Mammon to add new CBD products, including roll-ons, bath bombs, tattoo cream, moisturizers, creams, serums and body oils which make up the exciting new skincare product line. In conjunction with Taylor Mammon, IGNITE is also expanding its existing range of tinctures to offer different levels of potency and will also begin to offer 10ml CBD e-liquids for vape devices in the UK.
“It’s important to us and our partners that we continue to innovate and grow the IGNITE brand with new innovative products. We’re excited to be able to introduce a new line of skincare products that we know will introduce the IGNITE brand to a new audience,” said Curtis Heffernan, President of IGNITE. “Our business relationship with Taylor Mammon has been a great one for us in the past and we know that together we will continue to expand IGNITE globally.”